Kura Oncology’s (KURA) “Market Outperform” Rating Reiterated at JMP Securities

JMP Securities reissued their market outperform rating on shares of Kura Oncology (NASDAQ:KURA) in a research report report published on Monday,Benzinga reports. The firm currently has a $24.00 target price on the stock.

Several other equities analysts have also recently issued reports on KURA. Wall Street Zen upgraded Kura Oncology from a “sell” rating to a “hold” rating in a research report on Sunday, August 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kura Oncology in a research note on Wednesday, October 8th. Zacks Research cut shares of Kura Oncology from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 7th. Cantor Fitzgerald reissued an “overweight” rating on shares of Kura Oncology in a report on Thursday, June 26th. Finally, Guggenheim assumed coverage on shares of Kura Oncology in a research report on Thursday, September 4th. They set a “neutral” rating for the company. Ten equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Kura Oncology presently has a consensus rating of “Moderate Buy” and a consensus target price of $24.67.

Kura Oncology Stock Down 3.1%

KURA stock opened at $9.28 on Monday. Kura Oncology has a 52 week low of $5.41 and a 52 week high of $19.73. The company has a market capitalization of $805.50 million, a price-to-earnings ratio of -4.11 and a beta of 0.32. The firm’s 50-day moving average is $8.58 and its two-hundred day moving average is $6.97. The company has a current ratio of 6.16, a quick ratio of 6.16 and a debt-to-equity ratio of 0.02.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.15 by ($0.90). The firm had revenue of $15.29 million for the quarter, compared to analyst estimates of $64.95 million. On average, analysts forecast that Kura Oncology will post -2.44 earnings per share for the current fiscal year.

Insider Transactions at Kura Oncology

In related news, COO Kathleen Ford sold 6,892 shares of Kura Oncology stock in a transaction dated Monday, September 29th. The stock was sold at an average price of $8.94, for a total value of $61,614.48. Following the transaction, the chief operating officer owned 63,375 shares of the company’s stock, valued at approximately $566,572.50. This trade represents a 9.81% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Brian T. Powl sold 8,891 shares of the company’s stock in a transaction dated Monday, September 29th. The shares were sold at an average price of $8.94, for a total transaction of $79,485.54. Following the sale, the insider directly owned 99,676 shares of the company’s stock, valued at $891,103.44. This represents a 8.19% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 78,058 shares of company stock worth $697,839 in the last three months. Insiders own 6.40% of the company’s stock.

Hedge Funds Weigh In On Kura Oncology

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. State of Wyoming purchased a new position in Kura Oncology during the 1st quarter worth approximately $48,000. Merit Financial Group LLC purchased a new position in shares of Kura Oncology during the third quarter valued at $89,000. Magnetar Financial LLC purchased a new position in shares of Kura Oncology during the first quarter valued at $79,000. Tower Research Capital LLC TRC raised its position in Kura Oncology by 471.3% during the second quarter. Tower Research Capital LLC TRC now owns 12,071 shares of the company’s stock valued at $70,000 after buying an additional 9,958 shares during the period. Finally, Brighton Jones LLC purchased a new stake in Kura Oncology in the 3rd quarter worth about $108,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.